Please join us for the HPS Corporate Lending Fund First Quarter 2026 Shareholder Update Webcast

Portfolio

HLEND seeks to build a diversified portfolio of senior secured private credit investments in resilient, market-leading, upper-middle market companies that operate primarily in non-cyclical sectors.

Data as of March 31, 2026

$25.0B

Investments at Fair Value

9.3%

Portfolio Yield at Fair Value1

94%

Private Investments2

95%

First Lien Exposure3

99%

Floating Rate4

$255M

Weighted Average EBITDA5

Portfolio Companies89

Clear Filters
Company Name
Industry
Investment Type
Reference Rate & Spread11
Par Amount (thousands)
Amortized Cost (thousands)
Fair Value (thousands)
% of Total Portfolio
Bayou Intermediate II, LLC (Cordis) Health Care Equipment & Supplies S + 4.75% $214,422 179,443 179,788 0.72%
Advarra Holdings, Inc. (Advarra, Inc.) Life Sciences Tools & Services S + 4.50% $214,551 207,011 208,531 0.83%
Zendesk Inc (Zendesk, Inc.) Software S + 5.00% $216,057 196,292 193,175 0.77%
Valence Surface Technologies LLC Aerospace & Defense S + 7.00% $217,514 199,017 203,157 0.81%
Oak Funding LLC Financial Services S + 4.50% $220,000 198,342 198,690 0.79%
MB2 Dental Solutions, LLC Health Care Providers & Services S + 5.50% $220,599 204,529 206,404 0.83%
Empower Payments Investor, LLC (RevSpring) Financial Services S + 4.50% $221,794 209,431 210,242 0.84%
Zenith AcquisitionCo LLC (Novaria Holdings LLC) Aerospace & Defense S + 4.50% $222,361 150,510 150,515 0.60%
EasyPark Strategy AB Software N + 4.75% NOK 234,246 20,248 23,800 0.10%
Coding Solutions Acquisition, Inc. (CorroHealth) Health Care Providers & Services S + 5.00% $237,061 186,206 188,767 0.75%
Auditboard, Inc. Software S + 4.50% $244,465 242,554 239,625 0.96%
SW Ingredients Holdings, LLC (Spice World) Consumer Staples Distribution & Retail S + 5.00% $247,512 193,316 194,169 0.78%
Azurity Pharmaceuticals Inc (Azurity Pharmaceuticals) Pharmaceuticals S + 7.00% $250,486 246,526 243,345 0.97%
CCI Buyer, Inc. (Consumer Cellular) Wireless Telecommunication Services S + 5.00% $251,027 230,813 230,514 0.92%
Solis Mammography Buyer, Inc. (Solis Mammography) Health Care Providers & Services S + 5.00% $251,986 195,339 194,794 0.78%
Titan BW Borrower L.P. (Triumph Group Inc) Aerospace & Defense S + 5.38% (incl 2.88% PIK) $252,146 249,910 249,422 1.00%
Omega II AB (Fortnox AB) Software ST + 4.75% SEK 255,591 -125 270 0.00%
Meralm Bidco AB (Miss Group) IT Services N + 6.25% (incl 2.25% PIK) NOK 272,456 25,434 24,967 0.10%
PerkinElmer U.S. LLC (PerkinElmer) Life Sciences Tools & Services S + 4.75% $275,142 271,759 274,088 1.10%
Sentinel Buyer Corp. (SimpliSafe Holding Corporation) Commercial Services & Supplies S + 5.00% $278,618 254,950 255,367 1.02%
Wharf Street Ratings Acquisition LLC (KBRA) Capital Markets S + 4.75% $314,350 252,719 258,475 1.03%
DigiCert Inc Software S + 5.75% $362,527 322,758 316,669 1.27%
Severin Acquisition LLC (Powerschool Holdings, LLC) Software S + 4.75% (incl 2.25% PIK) $369,045 318,209 321,092 1.28%
AB Centers Acquisition Corporation (Action Behavior Centers LLC) Health Care Providers & Services S + 5.25% $395,029 352,519 353,944 1.42%
Meralm Bidco AB (Miss Group) IT Services ST + 6.25% (incl 2.25% PIK) SEK 427,755 41,271 40,079 0.16%

Engage with HLEND

Start Here

Footnotes

  1. Computed as (a) the annual stated interest rate or yield plus the annual accretion of discounts and less any annual amortization of premiums, as applicable, on accruing (i) debt and (ii) other income producing securities, divided by (b) total accruing (i) debt and (ii) other income producing securities (at fair value). Actual yields earned over the life of each investment could differ materially from the yields presented above. Please refer to HLEND’s prospectus and filings, including Form 10-Q or Form 10-K for fair value disclosures.
  2. Private Investments represents level 3 investments in the investment portfolio where inputs to the valuation methodology are unobservable and significant to overall fair value measurement. Private investments includes investments in joint ventures.
  3. Based on the aggregate fair value of the investment portfolio as of March 31, 2026.
  4. Percentage based on aggregate fair value of accruing debt.
  5. Calculated with respect to all level 3 investments (or, with respect to weighted average loan to value, all level 3 debt investments) in the investment portfolio for which fair value is determined by the Investment Adviser (in its capacity as the investment adviser of HLEND, with assistance, at least quarterly, from a third-party valuation firm, and overseen by HLEND’s Board of Trustees), and excludes quoted assets and investments in joint ventures. In the case of weighted average EBITDA only, excludes investments with no reported EBITDA or where EBITDA, in the Investment Adviser’s judgement made in its discretion, was not a material component of the original investment thesis, such as loan-to-value-based loans, NAV-based loans or reorganized equity. Weighted average EBITDA is weighted based on the fair value of the total applicable level 3 investments. Loan to value is calculated as net debt through each respective investment tranche in which HLEND holds an investment divided by enterprise value or value of underlying collateral of the portfolio company. Weighted average loan to value is weighted based on the fair value of the total applicable level 3 debt investments. Excludes investments on non-accrual status as of October 31, 2024. Figures are derived from the most recent financial statements from portfolio companies.
  6. Includes “last out” portions of first lien senior secured loans.
  7. Secured debt at the holding company level.
  8. Based on MSCI / S&P Global Industry Classification Standard (“GICS”) industry definition. Totals may not sum due to rounding. 
  9. All figures are as of March 31, 2026 unless otherwise indicated. % of total portfolio shown above is measured as total fair value of investments.
  10. Other includes structured finance investments.
  11. Contractual rates on preferred equity investments may represent preference accruals that are not recognized through investment income of the fund and as such are not included in the calculation of yield. The fair value of these investments may be influenced by the stated preference accrual or a minimum return threshold.